# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Ashwani Verma downgrades Coherus BioSciences (NASDAQ:CHRS) from Buy to Neutral and lowers the price target from ...
Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $...
HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $12 price...
Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:CHRS) with a Outperform and lowers the price target from $9...
HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $12 price...
Truist Securities analyst Robyn Karnauskas maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and lowers the price targe...
HC Wainwright & Co. analyst Douglas Tsao maintains Coherus BioSciences (NASDAQ:CHRS) with a Buy and raises the price tar...